NCX 466Cyclooxygenase-inhibiting nitric oxide donor CAS# 1262956-64-8 |
- Limonin
Catalog No.:BCN6057
CAS No.:1180-71-8
- Fosamprenavir Calcium Salt
Catalog No.:BCC1581
CAS No.:226700-81-8
- HIV-1 integrase inhibitor
Catalog No.:BCC1618
CAS No.:544467-07-4
- BMS-626529
Catalog No.:BCC1427
CAS No.:701213-36-7
- HIV-1 integrase inhibitor 2
Catalog No.:BCC1619
CAS No.:957890-42-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1262956-64-8 | SDF | Download SDF |
| PubChem ID | 49855334 | Appearance | Powder |
| Formula | C20H24N2O9 | M.Wt | 436.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
| Chemical Name | [(5S)-5,6-dinitrooxyhexyl] (2S)-2-(6-methoxynaphthalen-2-yl)propanoate | ||
| SMILES | CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)OCCCCC(CO[N+](=O)[O-])O[N+](=O)[O-] | ||
| Standard InChIKey | QTUSNUCZIUBIBF-LIRRHRJNSA-N | ||
| Standard InChI | InChI=1S/C20H24N2O9/c1-14(15-6-7-17-12-18(28-2)9-8-16(17)11-15)20(23)29-10-4-3-5-19(31-22(26)27)13-30-21(24)25/h6-9,11-12,14,19H,3-5,10,13H2,1-2H3/t14-,19-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Cyclooxygenase (COX)-inhibiting nitric oxide (NO) donor (CINOD). Inhibits COX-1 and COX-2 while releasing NO. Demonstrates higher efficacy than naproxen, its congener drug, in reducing levels of profibrotic cytokine transforming growth factor-β and oxidative stress in a mouse model of bleomycin-induced lung fibrosis. Orally available. |
NCX 466 Dilution Calculator
NCX 466 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2914 mL | 11.4571 mL | 22.9142 mL | 45.8285 mL | 57.2856 mL |
| 5 mM | 0.4583 mL | 2.2914 mL | 4.5828 mL | 9.1657 mL | 11.4571 mL |
| 10 mM | 0.2291 mL | 1.1457 mL | 2.2914 mL | 4.5828 mL | 5.7286 mL |
| 50 mM | 0.0458 mL | 0.2291 mL | 0.4583 mL | 0.9166 mL | 1.1457 mL |
| 100 mM | 0.0229 mL | 0.1146 mL | 0.2291 mL | 0.4583 mL | 0.5729 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Spautin-1
Catalog No.:BCC6420
CAS No.:1262888-28-7
- CCT241533
Catalog No.:BCC1462
CAS No.:1262849-73-9
- 25-Hydroxy VD2-D6
Catalog No.:BCC1305
CAS No.:1262843-46-8
- Trigonosin F
Catalog No.:BCN6403
CAS No.:1262842-73-8
- Penitrem A
Catalog No.:BCC7957
CAS No.:12627-35-9
- Benzoylmesaconine hydrochloride
Catalog No.:BCN5399
CAS No.:126266-38-4
- GS967
Catalog No.:BCC6401
CAS No.:1262618-39-2
- Assamicadine
Catalog No.:BCN1957
CAS No.:126260-96-6
- Fumitremorgin B
Catalog No.:BCN6453
CAS No.:12626-17-4
- (2R,3S)-Dihydrodehydroconiferyl alcohol
Catalog No.:BCN7886
CAS No.:126253-41-6
- Uralsaponin D
Catalog No.:BCN7895
CAS No.:1262489-44-0
- 24-Hydroxy-licoricesaponin A3
Catalog No.:BCN7896
CAS No.:1262326-47-5
- Paromomycin Sulfate
Catalog No.:BCC4694
CAS No.:1263-89-4
- DL-AP4 Sodium salt
Catalog No.:BCC7759
CAS No.:1263093-79-3
- 7-Chlorokynurenic acid sodium salt
Catalog No.:BCC7757
CAS No.:1263094-00-3
- CDK9 inhibitor 2
Catalog No.:BCC1466
CAS No.:1263369-28-3
- Pinobanksin 3-O-propanoate
Catalog No.:BCN7737
CAS No.:126394-70-5
- Nortropinyl cinnamate
Catalog No.:BCN1891
CAS No.:126394-79-4
- Colistin Sulfate
Catalog No.:BCC4653
CAS No.:1264-72-8
- SR 12813
Catalog No.:BCC7530
CAS No.:126411-39-0
- VTP-27999 Hydrochloride
Catalog No.:BCC2050
CAS No.:1264191-73-2
- Pyrrolam A
Catalog No.:BCN2040
CAS No.:126424-76-8
- Pyrrolam B
Catalog No.:BCN1986
CAS No.:126424-77-9
- 6-Ethoxygeniposide
Catalog No.:BCN7043
CAS No.:1264496-61-8
Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor.[Pubmed:22344408]
J Pharmacol Exp Ther. 2012 May;341(2):493-9.
Cyclooxygenase (COX)-inhibiting nitric oxide (NO) donors (CINODs) are designed to inhibit COX-1 and COX-2 while releasing NO. COX inhibition is responsible for anti-inflammatory and pain-relieving effects, whereas NO donation can improve microcirculation and exert anti-inflammatory and antioxidant actions. In an in vivo mouse model of bleomycin-induced lung fibrosis, we evaluated whether a prototype CINOD compound, (S)-(5S)-5,6-bis(nitrooxy)hexyl)2-(6-methoxynaphthalen-2-yl)propanoate (NCX 466), may show an advantage over naproxen, its congener drug not releasing NO. Bleomycin (0.05 IU) was instilled intratracheally to C57BL/6 mice, which were then treated orally with vehicle, NCX 466 (1.9 or 19 mg/kg), or an equimolar dose of naproxen (1 or 10 mg/kg) once daily for 14 days. Afterward, airway resistance, assumed as lung stiffness index, was assayed, and lung specimens were collected for analysis of lung inflammation and fibrosis. NCX 466 and naproxen dose-dependently prevented bleomycin-induced airway stiffness and collagen accumulation. NCX 466, at the highest dose, was significantly more effective than naproxen in reducing the levels of the profibrotic cytokine transforming growth factor-beta and the oxidative stress markers thiobarbituric acid reactive substance and 8-hydroxy-2'-deoxyguanosine. NCX 466 also decreased myeloperoxidase activity, a leukocyte recruitment index, to a greater extent than naproxen. A similar inhibition of prostaglandin E(2) was achieved by both compounds. In conclusion, NCX 466 has shown a significantly higher efficacy than naproxen in reducing lung inflammation and preventing collagen accumulation. These findings suggest that COX inhibition along with NO donation may possess a therapeutic potential in lung inflammatory diseases with fibrotic outcome.
